Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03749642
Other study ID # 039(1)PO16357
Secondary ID 2018-000133-12
Status Completed
Phase Phase 2
First received
Last updated
Start date November 22, 2018
Est. completion date June 6, 2020

Study information

Verified date May 2021
Source Aziende Chimiche Riunite Angelini Francesco S.p.A
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to collect preliminary information on the effect of three doses of trazodone/gabapentin FDC products on pain intensity in patients with painful diabetic neuropathy after 8-week treatment period.


Description:

The present phase II study is designed to collect preliminary data on the efficacy and safety of trazodone/gabapentin Fixed-Dose Combination (FDC)products for treatment of patients affected by painful diabetic neuropathy in a randomized controlled clinical trial. Diabetic peripheral neuropathic pain represents an important therapeutic challenge as its pathophysiology is not yet fully understood and pain relief is still unsatisfactory. The pharmacological treatments, with exception to those targeted to the glycemic control, are symptomatic and their use is limited by not universal efficacy, side effects or by the development of tolerance. A wide variety of drugs, used both alone and in combination, has shown to significantly reduce neuropathic pain when compared with placebo in randomized controlled trials, even though pain relief remains inadequate for most of the patients. In this contest, Angelini S.p.A is developing a fixed-dose combination medicinal product for the treatment of neuropathic pain containing low doses of active ingredients: trazodone, a widely used antidepressant drug, and gabapentin which is indicated for the treatment of neuropathic pain.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date June 6, 2020
Est. primary completion date June 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male and female patient of any ethnic origin between 18 and 75 years of age (limits included). 2. Neuropathic pain at feet/legs confirmed by Douleur Neuropatique 4 (DN4) score = 4 at Screening Visit. 3. Patient with bilateral distal symmetrical polyneuropathy confirmed by Toronto Clinical Neuropathy Scoring System (TCNSS) score > 5 at Screening visit. 4. Pain persisting or taking pain medication for neuropathic pain for at least 3 months. 5. Diabetic patient (type 1 or 2 diabetes mellitus) with value of glycated haemoglobin = 11% at Screening Visit and stable antidiabetic medication regimen for =30 days. 6. Patient who is currently not receiving treatment for diabetic neuropathic pain or patient who is receiving treatment, with drug/s other than gabapentin, and has completed the required washout. 7. Average daily pain score = 4 based on the 11-point Numeric Rating Scale (NRS) at Visit 0, calculated from a minimum of four pain ratings in daily electronic device entries during the baseline period. 8. Women of childbearing potential must have a negative pregnancy test at Screening Visit and have to agree not to start a pregnancy from the signature of the informed consent up to thirty days after the last administration of the investigational product, using an appropriate birth control method, such as combined estrogen and progestogen containing hormonal contraception (e.g. oral, intravaginal, transdermal), progestogen-only hormonal contraception (e.g. oral, injectable, implantable), intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. 9. Legally capable to give their consent to participate in the study (including personal data processing) and available to sign and date the written informed consent. Exclusion Criteria: 1. Known hypersensitivity to trazodone or gabapentin or any excipients of the test drugs. 2. Any other form of non-diabetic distal symmetric polyneuropathy or any other pain condition that can impair the study endpoint (e.g. painful conditions where the intensity of pain is significantly more severe than the diabetic peripheral neuropathic pain). 3. Concomitant treatment with medications for pain management that could not be discontinued. 4. Concomitant treatment with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, indinavir) or drugs known to prolong QT interval. 5. Use of trazodone or gabapentin in the previous 3 months. 6. Known history of previous non-responder to gabapentin treatment. 7. Use of high dose morphine (e.g. > 120 mg/day) at the Screening Visit. 8. Clinically significant abnormalities on physical examination, vital signs, elettrocardiogram, laboratory tests at Screening Visit that in the opinion of Investigator would compromise patient's participation in the study. 9. Active foot ulcer or previous major limb amputation. 10. Concurrent heart failure = 4 class according to New York Heart Association (NYHA) or myocardial infarction or angioplasty or by-pass graft procedures within the past 6 months. 11. Patient with increased risk of Torsade de Pointes (e.g. family history of long QT syndrome) or QTcF value higher than 450 msec (male) and QTcF value higher than 470 msec (female) at Screening Visit. 12. Transient ischemic attack or cerebral vascular accident within the past 6 months. 13. Glomerular Filtration Rate value < 50 ml/min calculated with Modification of Diet in Renal Disease formula. 14. Significant liver disease, defined as known active hepatitis or elevated liver enzymes over 3-fold the upper normal limit of laboratory normal ranges. 15. Patient with latent or known hereditary problems of galactose intolerance or the Lapp lactase deficiency or glucose-galactose malabsorption. 16. Positive urine drug screen for Central Nervous System active drugs (cocaine, opioids, amphetamines and cannabinoids) at Screening Visit. 17. Positive present history of glaucoma. 18. Hyperthyroidism, even if pharmacologically corrected. 19. Significant mental disorders. 20. Suicide risk score = 2 on question 9 of the Beck Depression Inventory-II (BDI-II) at Screening visit or Visit 0. 21. History of epilepsy or seizure events other than a single childhood febrile seizure. 22. History of alcohol or psychoactive substance abuse or addiction. 23. Use of neurological device (e.g. neurostimulation devices, etc). 24. Women during pregnancy or lactation period. 25. Inability to comply with the protocol requirements, instructions or study-related restrictions (e.g. uncooperative attitude, inability to return for study visits, improbability of completing the clinical study, etc). 26. Subject involved in the conduct of the study (e.g. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel, etc). 27. Participation to an interventional clinical trial within 3 months prior to Screening Visit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
trazodone/gabapentin 2.5/25 mg
The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
trazodone/gabapentin 5/50 mg
The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
trazodone/gabapentin 10/100
The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
Gabapentin
The total daily doses administered will be: 600 mg from day 0 to day 6 (±1) 900 mg from day 7 (±1) to day 13 (±1) 1200 mg from day 14 (±1) to day 20 (±1) 1800 mg from day 21 (±1) to day 56 (±2)
Placebo oral capsule
Two capsules, three times a day, for 8 weeks.

Locations

Country Name City State
Czechia Neurosanatio s.r.o. Litomyšl, 570 01
Czechia Cerebrovaskulární poradna, s.r.o. Ostrava - Poruba, 70800
Czechia Nemocnice Pardubického kraje a.s. Pardubická nemocnice Neurologická klinika Pardubice, 532 03
Czechia Diabetologická ambulance Milan Kvapil s.r.o. Praha 4, 149 00
Czechia Axon Clinical s.r.o Praha 5, 15000
Czechia FORBELI s.r.o. Praha 6, 160 00
Czechia Clintrial s.r.o. Praha, 100 00
France Fondation Hôtel Dieu Groupe SOS Service de Diabétologie Le Creusot, 71200
France GHR MSA - Hôpital Emile Muller Service de Diabétologie-Endocrinologie-Nutrition Mulhouse, 68100
France CHU de Nantes - Hôpital Guillaume-et-René-Laënnec Clinique d'Endocrinologie, maladies métaboliques et nutrition CIC Endocrino - Nutrition - UF 7015 Nantes Cedex 144 093
France Centre de Recherche Clinique G.H.M les Portes du Sud Departement d'Endocrinologie Venissieux, 69200
Poland Centrum Badan Klinicznych PI-House Gdansk, 80-546
Poland Silmedic Sp. z o.o. Katowice, 40-282
Poland Pro Familia Altera Poradnia Wielospecjalistyczna Katowice, 40-648
Poland Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Kraków, 31-261
Poland NZOZ Neuromed M. i M. Nastaj Sp. P. Lublin, 20-064
Poland Instytut Medycyny Wsi im. Witolda Chodzki Klinika Diabetologii Lublin, 20-090
Poland Centrum Medyczne HCP Sp. z o.o. Poznan, 61-485
Poland RCMed Oddzial Sochaczew Sochaczew, 96-500
Poland Nasz Lekarz Przychodnie Medyczne Torun, 87-100
Poland Medycyna Kliniczna Warszawa, 00-874
Poland Instytut Diabetologii Warszawa, 04-736
Poland WroMedica I. Bielicka, A. Strzalkowska s.c. Wroclaw, 51- 685
Poland Centrum Badan Klinicznych Osrodek Badan Wczesnej Fazy Wroclaw, 51-162
United Kingdom Medical Innovation Development and Research Unit (MIDRU) Heartlands Hospital Birmingham
United Kingdom Diabetes Centre Wythenshawe Hospital Manchester
United Kingdom Manchester Clinical Research Facility Manchester Royal Infirmary Manchester
United Kingdom Diabetes Centre George Eliot Hospital NHS Trust Nuneaton
United Kingdom Lancashire Clinical Research Facility The Avondale Unit Royal Preston Hospital Preston
United Kingdom Clinical Research Facility Royal Hallamshire Hospital Sheffield

Sponsors (2)

Lead Sponsor Collaborator
Aziende Chimiche Riunite Angelini Francesco S.p.A Chiltern International Inc.

Countries where clinical trial is conducted

Czechia,  France,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS). The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain]. Baseline - Day 56
Secondary Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS). The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain]. Baseline - Days 7, 14, 21, 28, 42
Secondary Percentage of responder patients Responder patients are defined as =30% and =50% reduction from baseline of the average daily pain score based on the 11-point NRS. Baseline - Day 56
Secondary Change of the average daily pain score based on the 11-point NRS between gabapentin and placebo as assay sensitivity. The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain]. Baseline - Day 56
Secondary Change of Brief Pain Inventory Short Form (BPI-SF) items 3, 4, 5, 6, 8 and 9 score. The BPI-SF is a numeric rating scale that assesses the severity of pain, its impact on daily functioning and other aspects of pain (e.g. location of pain, relief from medications). Items use a 0-10 numeric rating scale anchored at zero for "no pain" and 10 for "pain as bad as you can imagine" for Severity, and "does not interfere" to "completely interferes" for Interference. Baseline - Days 28, 56
Secondary Change of Neuropathic Pain Symptom Inventory (NPSI) total score. The NPSI is a self-questionnaire specifically designed to evaluate the different symptoms of neuropathic pain: It includes 10 descriptors plus two temporal items that allow discrimination and quantification of five distinct clinically relevant dimensions of neuropathic pain syndromes. Baseline - Days 28, 56
Secondary Change of Beck Depression Inventory - Second Edition (BDI-II) The BDI-II consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression and scored from 0 to 3. Baseline - Days 28, 56
Secondary Change of Hospital Anxiety and Depression Scale (HADS). The HADS is used to assess the level of anxiety and depression that a patient is experiencing. This is 14-item scale: seven related to the anxiety and seven to depression. Each item is scored from 0 to 3. Baseline - Days 28, 56
Secondary Change of Insomnia Severity Index (ISI). The ISI is a 7-item self-reported instrument measuring the patient's perception of his/her insomnia.Total score ranges from 0-28 and the following categorization is applicable: 0-7 = absence of insomnia; 8-14 = subthreshold insomnia; 15-21 = moderate insomnia; 22-28 = severe insomnia. Baseline - Days 28, 56
Secondary Change of Euroqol-5D-5L (EQ-5D-5L) The EQ-5D-5L consists of the EQ-5D descriptive system (five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression assessed as no problems, slight problems, moderate problems, severe problems and extreme problems) and the EQ visual analogue scale (where the patient self-rates his/her health on a vertical visual analogue scale from 'The best health you can imagine' to 'The worst health you can imagine'). Baseline - Days 28, 56
Secondary Clinical Global Improvement or Change (CGI-C). CGI-C provides a global rating of patient's Improvement and scores range from "0 - not assessed" through to "7 - very much worse". Baseline - Days 28, 56
Secondary Frequency of adverse events Monitoring of the treatment related adverse events. 65 days
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT05476276 - EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy Phase 2
Recruiting NCT05480228 - EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA Phase 2
Unknown status NCT01125215 - Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Phase 2/Phase 3
Not yet recruiting NCT05937984 - Treatment for Painful Diabetic Neuropathy N/A
Recruiting NCT05080530 - Vitamin D and Painful Diabetic Neuropathy N/A
Completed NCT04005287 - A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy Phase 2
Recruiting NCT03331614 - An Evaluation of an SCCD on the Symptomatology of Painful DPN N/A
Recruiting NCT03700528 - The Development of Contextual Cognitive Behavioural Approach to PDN N/A
Recruiting NCT04689984 - The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689958 - The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689971 - The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Not yet recruiting NCT04087941 - Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial Phase 2
Terminated NCT01129960 - Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Phase 3
Terminated NCT01056315 - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y Phase 2
Completed NCT00980746 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Phase 2
Completed NCT04786340 - A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy Phase 2
Completed NCT03769675 - Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation N/A
Completed NCT03755934 - Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy Phase 2
Not yet recruiting NCT05118217 - Microvascular Dysfunction in Diabetic Peripheral Neuropathy